These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
76 results:

  • 1. [Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma --Review].
    Xiao ZW; Qi L; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1295-1299. PubMed ID: 39192434
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Effect of Selinexor on Proliferation and Apoptosis of Acute Myeloid leukemia Kasumi-1 Cells].
    Lin LH; Gao SQ; Mei XQ; Lin DY; Chen YF; Lin SD; Zhuang LH; Lin CM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1085-1090. PubMed ID: 39192402
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Recent advances in AML with mutated NPM1.
    Ishikawa Y; Ushijima Y; Kiyoi H
    Int J Hematol; 2024 Nov; 120(5):556-565. PubMed ID: 39174699
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.
    Chaudhry S; Beckedorff F; Jasdanwala SS; Totiger TM; Affer M; Lawal AE; Montoya S; Tamiro F; Tonini O; Chirino A; Adams A; Sondhi AK; Noudali S; Cornista AM; Nicholls M; Afaghani J; Robayo P; Bilbao D; Nimer SD; Rodríguez JA; Bhatt S; Wang E; Taylor J
    Leukemia; 2024 Sep; 38(9):1894-1905. PubMed ID: 38997434
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells.
    Terasaki T; Semba Y; Sasaki K; Imanaga H; Setoguchi K; Yamauchi T; Hirabayashi S; Nakao F; Akahane K; Inukai T; Sanda T; Akashi K; Maeda T
    Leukemia; 2024 Sep; 38(9):1918-1928. PubMed ID: 38987275
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. xpo1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
    Ann Hematol; 2024 Jul; 103(7):2311-2322. PubMed ID: 38519605
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
    Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
    Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line treatment with Fixed-Duration Ibrutinib plus Venetoclax.
    Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
    Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
    Molica S; Tam C; Allsup D; Polliack A
    Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. xpo1 is a new target of homoharringtonine (HHT): Making NPMc
    Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
    Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Azacitidine Is Synergistically Lethal with xpo1 Inhibitor Selinexor in Acute Myeloid leukemia by Targeting xpo1/eIF4E/c-MYC Signaling.
    Long H; Hou Y; Li J; Song C; Ge Z
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047788
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.
    Han Y; Hu A; Qu Y; Xu Q; Wang H; Feng Y; Hu Y; He L; Wu H; Wang X
    Pharmacol Res; 2023 Mar; 189():106700. PubMed ID: 36796466
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by xpo1 inhibitors.
    Jing CB; Prutsch N; He S; Zimmerman MW; Landesman Y; Look AT
    Br J Haematol; 2023 May; 201(3):489-501. PubMed ID: 36746437
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic value and therapeutic targeting of xpo1 in chronic lymphocytic leukemia.
    Xu Z; Pan B; Miao Y; Li Y; Qin S; Liang J; Kong Y; Zhang X; Tang J; Xia Y; Zhu H; Wang L; Li J; Wu J; Xu W
    Clin Exp Med; 2023 Oct; 23(6):2651-2662. PubMed ID: 36738306
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of xpo1.
    Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
    Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
    Mansouri L; Thorvaldsdottir B; Sutton LA; Karakatsoulis G; Meggendorfer M; Parker H; Nadeu F; Brieghel C; Laidou S; Moia R; Rossi D; Catherwood M; Kotaskova J; Delgado J; Rodríguez-Vicente AE; Benito R; Rigolin GM; Bonfiglio S; Scarfo L; Mattsson M; Davis Z; Gogia A; Rani L; Baliakas P; Foroughi-Asl H; Jylhä C; Skaftason A; Rapado I; Miras F; Martinez-Lopez J; de la Serna J; Rivas JMH; Thornton P; Larráyoz MJ; Calasanz MJ; Fésüs V; Mátrai Z; Bödör C; Smedby KE; Espinet B; Puiggros A; Gupta R; Bullinger L; Bosch F; Tazón-Vega B; Baran-Marszak F; Oscier D; Nguyen-Khac F; Zenz T; Terol MJ; Cuneo A; Hernández-Sánchez M; Pospisilova S; Mills K; Gaidano G; Niemann CU; Campo E; Strefford JC; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2023 Feb; 37(2):339-347. PubMed ID: 36566271
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
    Janssen JJWM; Löwenberg B; Manz M; Biemond BJ; Westerweel PE; Klein SK; Fehr M; Sinnige HAM; Efthymiou A; Legdeur MCJC; Pabst T; Gregor M; van der Poel MWM; Deeren D; Tick LW; Jongen-Lavrencic M; van Obbergh F; Boersma RS; de Weerdt O; Chalandon Y; Heim D; Spertini O; van Sluis G; Graux C; Stüssi G; van Norden Y; Ossenkoppele GJ
    Leukemia; 2022 Sep; 36(9):2189-2195. PubMed ID: 35869267
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.
    Misund K; Hofste Op Bruinink D; Coward E; Hoogenboezem RM; Rustad EH; Sanders MA; Rye M; Sponaas AM; van der Holt B; Zweegman S; Hovig E; Meza-Zepeda LA; Sundan A; Myklebost O; Sonneveld P; Waage A
    Leukemia; 2022 Jul; 36(7):1887-1897. PubMed ID: 35643867
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.
    Ishikawa C; Mori N
    Invest New Drugs; 2022 Aug; 40(4):718-727. PubMed ID: 35477814
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Venetoclax enhances DNA damage induced by xpo1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.
    Yu H; Wu S; Liu S; Li X; Gai Y; Lin H; Wang Y; Edwards H; Ge Y; Wang G
    J Cell Mol Med; 2022 May; 26(9):2646-2657. PubMed ID: 35355406
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.